Prednisone News and Research

RSS

European approval for Taxotere (docetaxel) in prostate cancer

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.

4 Nov 2004

Improved risk classification for patients with acute lymphoblastic leukemia offers hope for eliminating irradiation

Improved risk classification for patients with acute lymphoblastic leukemia (ALL), coupled with more intensive intrathecal chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as a part of routine treatment.

1 Nov 2004

Mycophenolate mofetil is effective for managing symptoms of the most common type of lupus

Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys.

18 Oct 2004

Researchers have discovered an effective new way to treat giant cell arteritis

Mayo Clinic researchers have discovered an effective new way to treat giant cell arteritis (GCA), a debilitating cause of headaches, fatigue, muscle pain and even blindness. The findings of this research will be presented at the American College of Rheumatology Annual Scientific Meeting.

13 Oct 2004

Prostate cancer patients who no longer respond to hormone therapy may benefit from a combination of docetaxel and estramustine

Prostate cancer patients whose cancer has spread to other parts of the body and who no longer respond to hormone therapy may benefit from a combination of the cancer drugs docetaxel and estramustine, according to a new study published in the Oct. 8 issue of the New England Journal of Medicine.

8 Oct 2004

Men with advanced, incurable prostate cancer can benefit from docetaxel

An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.

7 Oct 2004

Breast cancer drug Taxotere extends life of prostate cancer patients

Men with androgen-independent (hormone-refractory) metastatic prostate cancer treated with the breast-cancer drug Taxotere (docetaxel) Injection Concentrate in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy

6 Oct 2004

Study hints at antioxidants being able to prevent and restore hearing loss

In a preliminary study, researchers find that vitamin E may be effective in restoring sudden onset hearing loss of unknown origin (idiopathic sudden hearing loss). These findings suggest that further research may reveal the role of antioxidants in the prevention and restoration of hearing loss.

18 Sep 2004

MRI is becoming more recognized as useful in the etiological investigation of sudden deafness

For the patient, sudden deafness can be terrifying. For the specialist, this disorder can be most challenging for the cause of sudden deafness cannot be readily determined by use of the most advanced diagnostic tests.

17 Sep 2004

Children who take steroid drugs for nephrotic syndrome do not suffer bone loss

Childhood nephrotic syndrome, which affects 3 out of 100,000 children, is the most common chronic kidney disease in children. Although it does not impair kidney function, it weakens the body's ability to remove water and salt from the blood, and causes swelling in the belly, legs, and around the eyes.

25 Aug 2004

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.

7 Aug 2004

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

A new clinical study to determine how people with rheumatoid arthritis (RA) evaluate improvements in disease symptoms will be carried out by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health.

5 Aug 2004

Thalidomide's role in fighting blood disorders, such as multiple myeloma

From the late 1950s to the end of 1961, thalidomide was a popular sedative and treatment for morning sickness until it was discovered to cause fetal malformations, which proved fatal within the first year of life in 40 percent of affected infants.

13 Jul 2004

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Johns Hopkins Kimmel Cancer Center clinicians were among those at leading institutions that have completed a three-year international study showing that docetaxel, a drug made from yew tree needles, decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy.

11 Jun 2004

America's first two WNV encephalitis cases of 2004 respond to treatment

GenoMed, Inc. has announced that the country's second case of West Nile virus encephalitis has responded promptly to its treatment approach. So far, GenoMed's treatment is showing a 100% response rate among 13 immunocompetent patients. The sooner the treatment is instituted, the more rapid and more complete the response.

10 Jun 2004

New drugs ease treatment of multiple myeloma

Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.

10 Jun 2004

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

$Untreated postmenopausal women with osteoporosis are at risk for first spinal fracture within one year$

Untreated postmenopausal women with osteoporosis are at risk for first spinal fracture within one year

Results of a new analysis found that, without treatment, one out of 13 postmenopausal osteoporotic women who were initially fracture-free were likely to experience a spinal fracture within one year.

28 Apr 2004

FDA approves Advair Diskus® for children with asthma

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) approved the use of Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.

22 Apr 2004